Clinical Trials Logo

Cannabis clinical trials

View clinical trials related to Cannabis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06235632 Enrolling by invitation - Cannabis Clinical Trials

Responsible Marijuana Sales Practices to Reduce the Risk of Selling to Intoxicated Customers

Start date: October 17, 2023
Phase: N/A
Study type: Interventional

The new recreational marijuana markets are contributing to polysubstance-impaired driving and other harms, especially when marijuana is used in combination with alcohol, by selling marijuana to obviously-intoxicated customers. In this study, the effectiveness of an intervention to reduce the risk of marijuana sales to obviously-intoxicated customers will be tested in the state-licensed recreational marijuana market in Oregon, one of the first states to ban such sales. The intervention will combine efforts by state regulators to increase deterrence of the state law prohibiting marijuana sales to obviously-intoxicated customers with training of store personnel to recognize signs of intoxication and refuse sales. It will also include testing the rate at which visibly intoxicated customers are refused alcohol at nearby establishments that sell alcohol either on-site or off-site

NCT ID: NCT05160688 Enrolling by invitation - Cannabis Clinical Trials

Changes in Cognition and Psychiatric Disorder Symptoms During Cannabis Abstinence Using a Novel Discordant Twin Design

Start date: May 5, 2023
Phase: N/A
Study type: Interventional

This study will test whether 42 days of cannabis abstinence, compared to continued cannabis use, is associated with improvements in cognition and psychiatric disorder symptoms. Identical twins, who are concordant on cannabis use, will be experimentally-manipulated to be discordant for 42 days. Each twin, within a twin pair, will be randomly assigned to either the contingency management condition, incentive-based protocol to promote cannabis abstinence, or control condition, no changes in cannabis use requested.

NCT ID: NCT01167556 Enrolling by invitation - Schizophrenia Clinical Trials

Family Motivational Intervention in Schizophrenia

FMI
Start date: March 2006
Phase: N/A
Study type: Interventional

Cannabis use by people with schizophrenia is associated with family distress and poor clinical outcomes. Therefore, an Family Motivational Intervention (FMI) was developed to help parents to motivate their child with a diagnoses of recent-onset schizophrenia to reduce cannabis use. In a single-blind randomised clinical trail with 75 patients with the diagnosis of schizophrenia, parents will be assigned to either FMI or to routine care. Assessments will be conducted at baseline and at a 10- and 22-month follow-up. The study hypothesis is that FMI will be more effective than routine care in reducing (a) cannabis use in patients and (b) distress and sense of burden in parents.